- Home
- LEDS vs BLRX Comparison
LEDS vs BLRX Comparison
Compare LEDS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEDS
- BLRX
- Stock Information
- Founded
- LEDS 2005
- BLRX 2003
- Country
- LEDS Taiwan
- BLRX Israel
- Employees
- LEDS N/A
- BLRX N/A
- Industry
- LEDS Semiconductors
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LEDS Technology
- BLRX Health Care
- Exchange
- LEDS Nasdaq
- BLRX Nasdaq
- Market Cap
- LEDS 11.8M
- BLRX 12.2M
- IPO Year
- LEDS 2010
- BLRX 2011
- Fundamental
- Price
- LEDS $2.59
- BLRX $2.98
- Analyst Decision
- LEDS
- BLRX Buy
- Analyst Count
- LEDS 0
- BLRX 2
- Target Price
- LEDS N/A
- BLRX $26.00
- AVG Volume (30 Days)
- LEDS 37.3K
- BLRX 26.4K
- Earning Date
- LEDS 04-15-2025
- BLRX 05-27-2025
- Dividend Yield
- LEDS N/A
- BLRX N/A
- EPS Growth
- LEDS N/A
- BLRX N/A
- EPS
- LEDS N/A
- BLRX N/A
- Revenue
- LEDS $4,794,000.00
- BLRX $28,940,000.00
- Revenue This Year
- LEDS N/A
- BLRX N/A
- Revenue Next Year
- LEDS N/A
- BLRX N/A
- P/E Ratio
- LEDS N/A
- BLRX N/A
- Revenue Growth
- LEDS N/A
- BLRX 502.92
- 52 Week Low
- LEDS $0.92
- BLRX $2.85
- 52 Week High
- LEDS $2.94
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- LEDS 73.67
- BLRX 38.75
- Support Level
- LEDS $2.18
- BLRX $3.01
- Resistance Level
- LEDS $2.94
- BLRX $3.61
- Average True Range (ATR)
- LEDS 0.19
- BLRX 0.21
- MACD
- LEDS 0.05
- BLRX 0.02
- Stochastic Oscillator
- LEDS 69.57
- BLRX 17.11
About LEDS SemiLEDS Corporation
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.